Hepatitis B virus (HBV) infection continues to be a major public health issue worldwide. HBsAg loss is associated with functional remission and improved long-term outcome, and is considered to be a 'functional cure' (also referred to as clinical or immunologic cure) for chronic hepatitis B. This ideal goal of therapy can be achieved using optimized combination regimens with direct-acting antivirals [eg nucleos(t)ide analogues (NAs)] and immunomodulators [eg pegylated interferon alpha2a (Peg-IFN)] in selected patients with chronic hepatitis B. Among different combination therapies currently available, those with NA lead-in followed by Peg-IFN in virally suppressed patients has been demonstrated to be effective. This review provides an updated overview of the evidence supporting the use of combination therapies and summarizes expert consensus on the roadmap to attain functional cure for chronic hepatitis B patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jvh.13126 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B-Authors' Reply.
Aliment Pharmacol Ther
January 2025
Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B.
Aliment Pharmacol Ther
January 2025
Liverpool Hospital, New South Wales, Sydney, Australia.
Revolutionizing the understanding of liver disease: Metabolism, function and future.
World J Hepatol
December 2024
Faculty of Medicine, National Autonomous University of Mexico, Mexico City 04360, Mexico.
The intersection between metabolic-associated steatotic liver disease (MASLD) and chronic hepatitis B virus (HBV) infection is an emerging area of research with significant implications for public health and clinical practice. Wang 's study highlights the complexities of managing patients with concurrent MASLD and HBV. The findings revealed that patients with concurrent MASLD-HBV exhibited more severe liver inflammation and fibrosis, whereas those with HBV alone presented a better lipid profile.
View Article and Find Full Text PDFHepatitis B virus-induced cirrhosis: Mechanisms, global variations, and treatment advances.
World J Hepatol
December 2024
Institute of Liver Diseases, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun 130061, Jilin Province, China.
We focus on hepatitis B virus (HBV)-induced cirrhosis, global differences, and the evolution of antiviral treatment strategies. Chronic HBV (CHB) infection affects more than 250 million people globally, leading to cirrhosis and hepatocellular carcinoma. The aim of this article was to synthesize the current understanding of the pathophysiological mechanisms and clinical consequences of HBV-induced cirrhosis, and explore differences in disease progression between geographic regions.
View Article and Find Full Text PDFTargeting hypoxia and angiogenesis in hepatocellular carcinoma: New insights and therapeutic strategies.
World J Hepatol
December 2024
Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China.
In this manuscript we comment on the article by Yang published recently, focusing on how hepatic angiopoietin-2 (Ang-2) transcription promote the progression of hepatocellular carcinoma (HCC). HCC is one of the most common and lethal malignancies worldwide, especially in regions with high hepatitis B virus infection rates. Ang-2 is a key mediator of angiogenesis and plays a significant role in the progression of chronic liver diseases towards HCC, particularly in the hypoxic microenvironment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!